Purpose: The primary aim of this study was to investigate volume effect and safety of up to 50 mL/kg BW 6% hydroxyethyl starch (HES) 130/0.4 in adult and pediatric patients undergoing major elective surgery. The need ...Purpose: The primary aim of this study was to investigate volume effect and safety of up to 50 mL/kg BW 6% hydroxyethyl starch (HES) 130/0.4 in adult and pediatric patients undergoing major elective surgery. The need to infuse human albumin may be reduced or avoided in Japan if these large doses 6% HES 130/0.4 can be infused. Methods: The study was an uncontrolled, open-labeled, multi-center trial. Fifteen adult and 5 pediatric patients undergoing major elective surgery received 6% HES 130/0.4 (Voluven®) with a maximum dose of 50 mL/kg from the start of surgery until 2 hours after the end of surgery according to a treatment algorithm. The primary efficacy endpoint was the volume effect of 6% HES 130/0.4 determined by the volume of saved albumin during the investigational period and the time course of hemodynamic stability in adult and pediatric patients. Safety parameters were fluid balance, hemodynamic and laboratory parameters ECG, local and systemic tolerance and adverse events. Results: Adult patients received a mean of 32.0 mL/kg of 6% HES 130/0.4. For 12 out of 15 adult patients an average amount of 1033.8 mL (18.6 mL/kg) albumin could be saved. The other 3 adult patients did not receive more than 1000 mL of HES 130/0.4. All pediatric patients received approximately 50 mL/kg of HES 130/0.4;for these patients an average amount of 39.9 mL/kg body weight albumin could be saved. The majority of adult patients, and all pediatric patients were hemodynamically stable at all 3 time points. The observed changes of the assessed laboratory parameters including hematological and coagulation parameters or in any other safety parameter determined did not reveal any safety concern related to the administration of 6% HES 130/0.4 up to doses of 50 mL/kg body weight. Conclusion: The study results indicate that 6% HES 130/0.4 has a reliable volume effect, could contribute to significant human albumin savings and was safe and well tolerated up to a maximum dose of 50 mL/kg body weight in adult and pediatric patients undergoing major elective surgery.展开更多
目的探讨羟乙基淀粉130/0.4氯化钠注射液在剖宫产术中的临床应用价值。方法将2013年1月—2014年6月210例行择期剖宫产产妇随机分为观察组及对照组各105例,观察组输注羟乙基淀粉130/0.4氯化钠注射液500 m L,对照组输注乳酸钠林格液500 m...目的探讨羟乙基淀粉130/0.4氯化钠注射液在剖宫产术中的临床应用价值。方法将2013年1月—2014年6月210例行择期剖宫产产妇随机分为观察组及对照组各105例,观察组输注羟乙基淀粉130/0.4氯化钠注射液500 m L,对照组输注乳酸钠林格液500 m L,然后实施腰-麻联合麻醉。结果 2组产妇的均顺利完成手术,无呼吸抑制,脉搏血氧饱和度在98%-100%,术前平均动脉压、心率比较无显著性差异（P〉0.05）;观察组术中平均动脉压高于对照组;心率、低血压发生率,麻黄碱总用量低于对照组（P〈0.05）。结论腰-硬联合麻醉行剖宫产手术前输注羟乙基淀粉130/0.4氯化钠注射液,能有效减少术中低血压的发生,是安全可靠的措施。展开更多
文摘Purpose: The primary aim of this study was to investigate volume effect and safety of up to 50 mL/kg BW 6% hydroxyethyl starch (HES) 130/0.4 in adult and pediatric patients undergoing major elective surgery. The need to infuse human albumin may be reduced or avoided in Japan if these large doses 6% HES 130/0.4 can be infused. Methods: The study was an uncontrolled, open-labeled, multi-center trial. Fifteen adult and 5 pediatric patients undergoing major elective surgery received 6% HES 130/0.4 (Voluven®) with a maximum dose of 50 mL/kg from the start of surgery until 2 hours after the end of surgery according to a treatment algorithm. The primary efficacy endpoint was the volume effect of 6% HES 130/0.4 determined by the volume of saved albumin during the investigational period and the time course of hemodynamic stability in adult and pediatric patients. Safety parameters were fluid balance, hemodynamic and laboratory parameters ECG, local and systemic tolerance and adverse events. Results: Adult patients received a mean of 32.0 mL/kg of 6% HES 130/0.4. For 12 out of 15 adult patients an average amount of 1033.8 mL (18.6 mL/kg) albumin could be saved. The other 3 adult patients did not receive more than 1000 mL of HES 130/0.4. All pediatric patients received approximately 50 mL/kg of HES 130/0.4;for these patients an average amount of 39.9 mL/kg body weight albumin could be saved. The majority of adult patients, and all pediatric patients were hemodynamically stable at all 3 time points. The observed changes of the assessed laboratory parameters including hematological and coagulation parameters or in any other safety parameter determined did not reveal any safety concern related to the administration of 6% HES 130/0.4 up to doses of 50 mL/kg body weight. Conclusion: The study results indicate that 6% HES 130/0.4 has a reliable volume effect, could contribute to significant human albumin savings and was safe and well tolerated up to a maximum dose of 50 mL/kg body weight in adult and pediatric patients undergoing major elective surgery.
文摘目的:探讨6%羟乙基淀粉(HES)130/0.4对骨折创伤兔子血清白蛋白、微血管白蛋白渗漏、炎性因子的影响。方法:将20只健康雌性大白兔随机分为模型组和HES组,各10只,均采用钝器敲打后肢造成后肢骨折,行骨折切开内固定术。术后,模型组注射10 m L/kg生理盐水,HES组注射10 m L/kg 6%HES 130/0.4,连续3 d。比较两组血清白蛋白水平、微血管白蛋白渗漏情况以及白细胞介素-6(IL-6)、C反应蛋白(CRP)、降钙素原(PCT)水平。结果:术后72 h,两组血清白蛋白水平低于术前,但HES组高于模型组,差异有统计学意义(P<0.05);HES组肠系膜微血管白蛋白渗漏率低于模型组,差异有统计学意义(P<0.05);两组血清IL-6、CRP以及PCT水平高于术前,但HES组低于模型组,差异有统计学意义(P<0.05)。结论:骨折创伤兔子术后存在血清白蛋白水平下降、炎性因子水平升高情况,给予6%HES 130/0.4治疗可以减小血清白蛋白降低幅度,下调IL-6、CRP以及PCT水平,改善白蛋白渗漏情况。
文摘目的探讨剖宫产麻醉前羟乙基淀粉静脉预注预防低血压的临床价值。方法 2016年1月—2017年12月该院择期剖宫产孕妇110例随机分为分为观察组及对照组各55例,观察组及对照组分别应用6%羟乙基淀粉130/0.4注射液预扩容及林格氏液,,均为500 mL,30 min内输完,在L2～3间隙进行腰-硬联合麻醉。结果两组均顺利完成剖宫产手术,两组手术时间[(0.98±0.13)h vs (1.01±0.15)h]、术中出血量[(110.58±22.36)mL vs (107.38±19.47)mL]、Apgar评分[(9.33±0.27)分vs (9.28±0.30)分]差异无统计学意义(t=0.22、0.17、0.16,P>0.05);观察组低血压5.45%、不良反应3.64%、麻黄碱用量(7.08±1.27)mg低于对照组的20.00%,18.18%、(16.55±4.22)mg(χ~2=4.02、5.28,t=6.22,P<0.05),结论预注羟乙基淀粉130/0.4氯化钠注射液后能够明显地减轻腰硬联合麻醉后血流动力学的变化,发挥持久的扩容效果,值得临床应用。
文摘目的探讨羟乙基淀粉130/0.4氯化钠注射液在剖宫产术中的临床应用价值。方法将2013年1月—2014年6月210例行择期剖宫产产妇随机分为观察组及对照组各105例,观察组输注羟乙基淀粉130/0.4氯化钠注射液500 m L,对照组输注乳酸钠林格液500 m L,然后实施腰-麻联合麻醉。结果 2组产妇的均顺利完成手术,无呼吸抑制,脉搏血氧饱和度在98%-100%,术前平均动脉压、心率比较无显著性差异（P〉0.05）;观察组术中平均动脉压高于对照组;心率、低血压发生率,麻黄碱总用量低于对照组（P〈0.05）。结论腰-硬联合麻醉行剖宫产手术前输注羟乙基淀粉130/0.4氯化钠注射液,能有效减少术中低血压的发生,是安全可靠的措施。
